Barclays PLC Altimmune, Inc. Put Options Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
Put Options
1 transactions
Others Institutions Holding ALT
# of Institutions
186Shares Held
39.3MCall Options Held
913KPut Options Held
743K-
Black Rock Inc. New York, NY5.32MShares$40.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.98MShares$37.6 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.88MShares$29.3 Million0.01% of portfolio
-
State Street Corp Boston, MA3.41MShares$25.8 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$20.8 Million1.44% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $370M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...